CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

被引：19
|
作者：
Agha, Mounzer E.
Cohen, Adam D.
Madduri, Deepu
Cohen, Yael C.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
[4] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
[5] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[6] Univ Ziekenhuizen Leuven, Leuven, Belgium
[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[8] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[9] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[11] Univ Hosp Heidelberg, Heidelberg, Germany
[12] Univ Cologne, Cologne, Germany
[13] Janssen R&D, Raritan, NJ USA
[14] Janssen Global Serv LLC, Raritan, NJ USA
[15] Legend Biotech USA Inc, Piscataway, NJ USA
[16] Legend Biotech USA Inc, Somerset, NJ USA
[17] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8013
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [42] EFFICACY AND ADVERSE EVENTS AFTER CILTACABTAGENE AUTOLEUCEL TREATMENT IN THE CARTITUDE-4 AS-TREATED POPULATION CONSISTING OF PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA WHO RECEIVED 1-3 PRIOR LINES OF THERAPY
    Applewhite, Ishmael
    Elfrink, Gwen
    Esselmann, Jean
    Lonardi, Carolina
    Florendo, Erika
    Sidiqi, M. Hasib
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [43] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
    Shah, Nina
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Finney, Olivia
    Martin, Nathan
    Agarwal, Amit
    Rowe, Everton
    Campbe, Timothy B.
    San-Miguel, Jesus F.
    BLOOD, 2021, 138
  • [44] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
    Lin, Yi
    Raje, Noopur S.
    Berdeja, Jesus G.
    Siegel, David S.
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Massaro, Monica
    Petrocca, Fabio
    Caia, Andrea
    Yang, Zhihong
    Campbell, Timothy B.
    Hege, Kristen
    Munshi, Nikhil C.
    Kochenderfer, James N.
    BLOOD, 2020, 136
  • [45] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial
    Weisel, K.
    Einsele, H.
    Goldschmidt, H.
    Delforge, M.
    San Miguel, J.
    Bertin, K. B.
    Tahir, M.
    Lewis, H.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94
  • [46] Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
    Mailankody, Sham
    Jakubowiak, Andrzej J.
    Htut, Myo
    Costa, Luciano J.
    Lee, Kelvin
    Ganguly, Siddhartha
    Kaufman, Jonathan L.
    Siegel, David Samuel DiCapua
    Bensinger, William
    Cota, Mariana
    Doerr, Thomas
    DeVries, Todd
    Wong, Sandy Wai Kuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
    Goel, Utkarsh
    Dima, Danai
    Davis, James
    Ahmed, Nausheen
    Shaikh, Hira
    Lochner, Jonathan
    Abdallah, Al-Ola
    Khouri, Jack
    Hashmi, Hamza
    Anwer, Faiz
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (06) : 817 - 823
  • [48] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Z.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Stewart, A. Keith
    Hari, Parameswaran
    Htut, Myo
    Lesokhin, Alexander
    Deol, Abhinav
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Avigan, David
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Deraedt, William
    Zhuang, Sen Hong
    Infante, Jeffrey
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Rizvi, Syed
    Fan, Frank
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    LANCET, 2021, 398 (10297): : 314 - 324
  • [49] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
    Braverman, J.
    Dhanda, D. S.
    Moshkovich, O.
    Lanar, S.
    Miera, M.
    Williams, A. E.
    Murphy, R.
    Devlen, J.
    Hege, K.
    Campbell, T. B.
    VALUE IN HEALTH, 2021, 24 : S61 - S61
  • [50] Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus F.
    Bertin, Kaitlyn B.
    Tahir, Muna J.
    Lewis, Hannah B.
    Wang, Julie
    Braverman, Julia
    Campbell, Timothy B.
    Dhanda, Devender
    Munshi, Nikhil C.
    BLOOD, 2020, 136
12345